Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
A Study of the Effectiveness and Safety of Galantamine Hydrobromide on Cognitive Impairment in Patients With Schizophrenia.
This study has been completed.
Study NCT00077727 Information provided by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
First Received: February 11, 2004 Last Updated: March 17, 2008
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Schizophrenia
More general conditions related to this trial
Mental Disorders
Schizophrenia and Disorders with Psychotic Features
Additional drug interventions recognized in this trial
Antipsychotic Agents
Cholinesterase Inhibitors
Galantamine
More general drug interventions related to this trial
Autonomic Agents
Central Nervous System Agents
Central Nervous System Depressants
Cholinergic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Nootropic Agents
Parasympathomimetics
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Therapeutic Uses
Tranquilizing Agents
Sponsors listed in this trial
Johnson &Johnson Pharmaceutical Research &Development, L.L.C.
Back to top of Main Content
